Hayes: Cp circulating 'liquid' vs tissue biopsy slide. CTC and ctDNA as rare events; liquid biopsy represents the entire pt #AACR18
6:30pm April 16th 2018 via Hootsuite
Hayes: Tumor Grade/prognosis; '70's: McGuire: estrogen receptor, endocrine Rx; 80's Slamon: HER2/trastuzumab. #AACR18
6:29pm April 16th 2018 via Hootsuite
Hayes: 1870's Virchow introduce microscopic pathology; 1890's Roentgren: Dx radiology; 1910: Osler differential Dx. 1950's Bloom #AACR18
6:28pm April 16th 2018 via Hootsuite
Daniel Hayes (Univ MI) "Personalized", or "Precision" medicine? "New tools for an old trade!" 100's of years of history... #AACR18
6:27pm April 16th 2018 via Hootsuite
Dawson: Richter's Syndrome: could track changes over time. Shows low-pass WGS CN changes and changes over time under Rx #AACR18
6:25pm April 16th 2018 via Hootsuite
Dawson: ctDNA reflects disease burden following ibrutinib - example of CTC / ctDNA was complementary. ctDNA dynamic; CTC not avail. #AACR18
6:22pm April 16th 2018 via Hootsuite
Dawson: Relapsed CLL pts w/novel Rx; could ID differences between Rx. Venetoclax '17 https://t.co/E8rxsf3cCd #AACR18
6:21pm April 16th 2018 via Hootsuite
Dawson: Final example is resp to Rx and clonal evolution. CTC and ctDNA can be complementary in CLL. Want to know leukemic crypts #AACR18
6:19pm April 16th 2018 via Hootsuite
Dawson: MRD in StgIII (can't post), K-M curves; promise to risk stratify. For molecular profiling: EGFR the example. #AACR18
6:17pm April 16th 2018 via Hootsuite
Dawson: ctDNA during surveillance to detect early relapse - here stgII colon ca https://t.co/P0xRQ3jNV9 #AACR18
6:13pm April 16th 2018 via Hootsuite
Dawson: Quantitative - enumeration, or tumor burden; can also track clonal evol. No one single clin application #AACR18
6:11pm April 16th 2018 via Hootsuite
Dawson: Methods of analysis - no gold std or single platform; often PCR approaches, sc sequencing, or in vitro propagation. #AACR18
6:10pm April 16th 2018 via Hootsuite
Sarah-Jane Dawson (Peter MacCallum Melbourne AU): CTCs and ctDNA: Complementary Biomarkers for Precision Medicine #AACR18
6:09pm April 16th 2018 via Hootsuite
Luis Diaz (MSKCC NY): SU2C Colorectal Cancer Dream Team: Targeted Genomic, Metabolic, and Immunological Vulnerabilities of CRC #AACR18
2:39pm April 16th 2018 via Hootsuite
Landau: Concl - deep learning read-based mutation detection for ultra-low VAF, integrating CNV and SNV for 100-fold better sens #AACR18
2:36pm April 16th 2018 via Hootsuite
Landau:Depended on depth of mutation and mutation load, can go to 1:1,000,000. #AACR18
2:32pm April 16th 2018 via Hootsuite
Landau: Idea - look for a wider target to make up for lack of presence of mutation below the 'floor. Shows 2 orders of mag improvemt #AACR18
2:31pm April 16th 2018 via Hootsuite
Landau: Per 5L of blood, about 5,000,000 genomes. In a blood draw 500 Genome Equivalents. #AACR18
2:28pm April 16th 2018 via Hootsuite
Landau: real-world cfDNA sensitivity 'limited to >1:1000'. 0.1% - what about below that? Why: a sampling process #AACR18
2:27pm April 16th 2018 via Hootsuite
Landau: 97% of CLLs sign evolved in relapse. What are quantitative dynamics? #AACR18
2:19pm April 16th 2018 via Hootsuite
Landau: Tackling thousands of diseases at a molecular level. Is CLL a good place to start? Interatumoral heterogeneity #AACR18
2:18pm April 16th 2018 via Hootsuite
Dan Landau (Weill-Cornell NY): SU2C Innovative Grantee: Dynamic Measurement of the Evolving Cancer Genome to Guide Pers Ther Opt #AACR18
2:17pm April 16th 2018 via Hootsuite
Q: Considered CTC's? Velculescu: ctDNA is about 10-fold higher; for early det, felt that ctDNA was preferable #AACR18
2:15pm April 16th 2018 via Hootsuite
A2: Velculescu: Also have to be cost-effective; SU2C transitions from tech-dev to implementation #AACR18
2:12pm April 16th 2018 via Hootsuite
Q: CRC in young males is rising Velculescu: Colonoscopies for screening is low; stool biomarker is very simple to implement #AACR18
2:11pm April 16th 2018 via Hootsuite
Velculescu: 'It may have more impact than all therapies combined' - if screening and early detection method can expand like this #AACR18
2:08pm April 16th 2018 via Hootsuite
Velculescu: Spin-off ctDNA intervention study; preventing recurr. Use ctDNA to ID pts and then Rx w/adjuvant chemo. #AACR18
Velculescu: Now nat'l effort in Netherlands; expect accrual rate to accelerate w/14 hospitals. StgII every 6 months post-resection #AACR18
2:06pm April 16th 2018 via Hootsuite
Velculescu: 58 genes, 59k base target: chart across multiple cancer types. 59%-71% of early-stage br, ov, lu or CR cancers #AACR18
2:04pm April 16th 2018 via Hootsuite
Velculescu: Targeted Error Correction (TEC-Seq) '17 Science TM https://t.co/aHTa6Maqdd reducing error rate; looked at 200pts #AACR18
2:02pm April 16th 2018 via Hootsuite
Velculescu: For TMB and checkpoint inh: 13% pts reclassified, showed changes to K-M curve effects #AACR18
2:00pm April 16th 2018 via Hootsuite
Velculescu: Extrapolating, suggests >500K FP and FN changes in TCGA (!!) #AACR18
Velculescu: 9 tumor types, 74% concordant; 10% somatic muts missed; 16% likely FP's in TCGA. Indiv tumor loads differed by 95% fewer #AACR18
1:59pm April 16th 2018 via Hootsuite
Velculescu: Tool called cerebrum (Wood et al, submitted) shows much improved sens/spec. Applied to TCGA first 1,368 samples #AACR18
1:58pm April 16th 2018 via Hootsuite
Velculescu: ctDNA sens and spec is key; dev machine learning:multiple characteristics to ID tumor-spec mutations vs germline & noise #AA
1:57pm April 16th 2018 via Hootsuite
Velculescu: FIT screening - n=13.5k volunteers. For the 2nd (recurrence of hi-risk stgII CRC) Fig from '17 https://t.co/tNo5e9jAuW #AACR18
1:56pm April 16th 2018 via Hootsuite
Velculescu: Screening: protein analysis via MS in stool. 4-protein marker panels. '17 ref https://t.co/LAzivefdab #AACR18
1:55pm April 16th 2018 via Hootsuite
Velculescu: 2) High risk recurrence of stage II CRC, using ctDNA. #AACR18
1:53pm April 16th 2018 via Hootsuite
Velculescu: The case is becoming clearer for early detectoin - 1.2M CRC cases/yr. 150K in US, 15K in NL. 680K deaths/yr 1) screening #AACR18
Victor Velculescu (Johns Hopkins MD): SU2C-Dutch Cancer Society Colorectal Cancer Early Detection: Novel Detection Methodologies #AACR18
1:51pm April 16th 2018 via Hootsuite
Swisher: Restore HR a theme; replication fork stability may be impt. Need biopsies at progression - essential to know resistance #AACR18
1:47pm April 16th 2018 via Hootsuite
Swisher: Hypomorphic BRCA1/2 alleles - restoring HR fn (Wang et al JCI 2016). Concl: Pt resist is clin predictor. #AACR18
1:46pm April 16th 2018 via Hootsuite
Swisher: Hi hi-grade serous ov carcinoma, RAD51D case where reversion mut detected only in progressing spleet metastises #AACR18
1:38pm April 16th 2018 via Hootsuite
Swisher: From '08 https://t.co/dsR38anGG5 summarizes secondary BRCA2 mutations causing cisplatin resistance #AACR18
1:37pm April 16th 2018 via Hootsuite
Swisher: BRCA1 promotes end resection; BRCA2 loads RAD1. Also both protect the replication fork #AACR18
1:35pm April 16th 2018 via Hootsuite
Swisher: PARPi model of synthetic lethality - three common models. BRCA1/2 functions in more than 1 way. #AACR18
Elizabeth Swisher (Univ WA): SU2C-Ovarian Cancer Res Fund Alliance: Predicting PARP Inhibitor Resistance #AACR18
1:34pm April 16th 2018 via Hootsuite
Stumpe:They are actually exihibiting at #AACR18 (booth 4133), looking for early access testers.
9:38am April 16th 2018 via Hootsuite
Stumpe: Shows preliminary ROC, with AUC 0.96-0.98 for mPC/mBC. Also trainable to other areas; % of tumor, length, or rare events #AACR18
9:37am April 16th 2018 via Hootsuite
Stumpe: Shows images from the microscope, a predicted heatmap, and IHC of the same slide #AACR18
9:35am April 16th 2018 via Hootsuite
